Shopping Cart 0
Cart Subtotal
USD 0

Endo International Plc (ENDP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Endo International Plc (Endo) is a specialty healthcare company that develops, manufactures and commercializes various branded pharmaceutical products, generic pharmaceuticals and other products through its operating companies. It sells generic products principally in the US in various categories including urology, pain management, central nervous system (CNS) disorders, immunosuppression, cancer, cardiovascular diseases and women's health, among others. The company offers branded pharmaceuticals for conditions related to urology, orthopedics, endocrinology and pain management. Endo also provides over-the-counter (OTC) products, which include dermatological products and anti-infectives. The company sells its products through independent wholesale distributors, to retailers, government agencies, doctors, clinics, independent retail and specialty pharmacies and independent specialty distributors. Endo is headquartered in Dublin, Ireland.

Endo International Plc (ENDP)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 6

List of Figures 7

Endo International Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Endo International Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9

Endo International Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Endo International Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

Endo International Plc, Medical Devices Deals, 2012 to YTD 2018 13

Endo International Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14

Endo International Plc, Pharmaceuticals & Healthcare, Deal Details 18

Asset Purchase 18

Endo International Acquires Portfolio of Branded and Generic Products 18

Endo International Completes Acquisition of Sumavel DosePro Migraine Therapy Business from Zogenix 19

Par Pharma to Acquire Certain Assets of Nuray Chemicals for USD20 Million 20

Paladin Labs To Acquire Antibiotic Binotal In Latin America From Bayer 21

Par Pharma Completes Acquisition Of Generic Products From Watson Pharma And Actavis 22

Endo Pharma Acquires US Patents For Oxymorphone From Johnson Matthey 23

Private Equity 24

Endo International Sells Grupo Farmaceutico Somar to Advent International 24

Altaris Capital Partners Completes Acquisition Of HealthTronics From Endo Health Solutions For USD 130 Million 25

TPG Capital Completes Acquisition Of Par Pharma, Generic Drug Company, For USD 1.9 Billion 26

Partnerships 28

Endo Enters into Distribution Agreement with Bioprojet SCR 28

IntelGenx Enters into Co-Development Agreement with Endo Ventures 29

ARIAD Pharma Enters into Distribution Agreement with Paladin 30

Vyrix Pharma Enters Into Distribution Agreement With Paladin Labs For Zertane 31

IntelGenx Enters Into Development And Commercialization Agreement With Par Pharma For Two New Products 32

Auxilium Pharma Enter Into Co-Development Agreement with Swedish Orphan Biovitrum For Xiapex 33

Moberg Extends Distribution Agreement With Paladin Labs For Kerasal Nail 34

GVK Biosciences Enters Into Research Agreement With Endo Pharma 35

Paladin Labs Enters Into Distribution Agreement With Allergy Therapeutics For Pollinex-R 36

Paladin Labs Enters Into Distribution Agreement With Moberg Derma For Emtrix 37

Par Pharma Enters Into Distribution Agreement With AstraZeneca For Atacand HCT 38

Auxilium Pharma Enters Into Co-Promotion Agreement With GlaxoSmithKline For Testim 1% 39

Mersana Therapeutics Enters Into Co-Development Agreement With Endo Pharma 40

Licensing Agreements 41

Endo Ventures Enters into Licensing Agreement with Nevakar 41

Paladin Labs Enters into Licensing Agreement with Veloxis Pharma 42

Endo International Amends Licensing Agreement with BioSpecifics Technologies 43

Endo Pharma Holdings Amends Licensing Agreement with Grunenthal 44

Auxilium Exercises Option For Licensing Agreement With Biospecifics To Include Potential Treatment of Cellulite As Additional Indication 45

QrxPharma Enters Into Licensing Agreement With Paladin Labs For Moxduo 47

Auxilium Pharma Enters Into Licensing Agreement With Actelion Pharma For XIAFLEX 49

Sucampo Pharma and R-Tech Ueno Enter into Licensing Agreement with Par Pharma 51

Paladin Labs Enters Into Licensing Agreement With Bioniche Life Sciences 52

Paladin Labs Enters Into Licensing Agreement With Apeiron Biologics For APN311 54

Par Pharma Enters Into Licensing Agreement With Handa Pharma For Seroquel XR 55

Paladin Labs Enters Into Licensing Agreement With Dynamiclear For Dynamiclear Rapid 56

Nuvo Research Enters Into Licensing Agreement With Paladin Labs For Synera 57

Par Pharma Enters Into Licensing Agreement With Handa Pharma For ANDA 58

Equity Offering 59

Endo International Raises USD2.3 Billion in Public Offering of Shares 59

Debt Offering 61

Endo International Prices Private Placement of 5.875% Notes Due 2024 for USD300 Million 61

Endo Prices Private Placement of Notes Due 2023 for USD1.6 Billion 62

Endo International Prices Private Placement of 6% Notes Due 2023 for USD1.64 Billion 63

Endo International Prices Private Placement of 6% Notes Due 2025 for USD1.2 Billion 64

Endo International Completes Private Placement of 5.375% Notes Due 2023 for USD750 Million 65

Endo Health Solutions Completes Private Placement Of Notes Due 2022 For USD 700 Million 66

Auxilium Pharma Completes Public Offering Of Notes Due 2018 For USD 350 Million 67

Par Pharma Completes Private Placement Of Notes Due 2020 For USD 490 Million 68

Asset Transactions 69

Lannett Acquires Portfolio of Generic Products from Endo International 69

Mayne Pharma Acquires Commercial Rights to Fentanyl TDS from Par Pharma 70

Rising Pharma to Acquire Three ANDAs from Endo International 71

Braeburn Pharma Acquires Risperidone Implant from Endo Pharma 72

Nuvo Research Reacquires Pennsaid Rights from Paladin Labs 73

Rising Pharma Acquires Doxercalciferol, Paricalcitol and Dutasteride from Par Pharma 74

Trendlines Acquires Intellectual Property from Endo 75

AsanaBioSciences Completes Acquisition of Drug Discovery Platform from Endo Pharma 76

Acquisition 77

Endo Ventures and Par Pharma to Acquire Somerset Therapeutics from Meddham Holdings 77

Par Formulations to Acquire Wintac 78

Acino Pharma Acquires Litha Healthcare from Endo International 79

Endo International Acquires Par Pharma from TPG Capital for USD8.05 Billion 80

Par Pharma Acquires Innoteq for USD27 Million 82

Endo International Acquires Auxilium Pharma for USD2.6 Billion 83

Par Pharma Reportedly Acquires Ethics Bio Lab 85

Endo International Completes Acquisition of Dava Pharma for USD600 Million 86

Endo International Completes Acquisition of Grupo Farmaceutico Somar 87

Endo Health Solutions Completes Acquisition Of Paladin Labs For USD 1.6 Billion 88

Par Pharma Acquires JHP Group for USD488 Million 91

Endo Health Solutions Completes Acquisition Of Boca Pharmacal For USD 225 Million 92

Paladin Labs Acquires Triton Pharma 94

Paladin Labs Completes Acquisition Of Allon Therapeutics 95

Auxilium Pharma Acquires Actient From GTRC 96

Paladin Labs Completes Acquisition Of Majority Stake In Ativa Pharma 98

Paladin Labs Completes Acquisition Of Remaining 55.01% Stake In Pharmaplan, Generic Pharma Company 99

Litha Healthcare Group Completes Acquisition Of Pharmaplan From Paladin Labs For USD 60.7 Million 100

Par Pharma Completes Acquisition Of Edict Pharma, Generic Pharma Company, For USD 24.9 Million 102

Endo International Plc-Key Competitors 103

Endo International Plc-Key Employees 104

Endo International Plc-Locations And Subsidiaries 106

Head Office 106

Other Locations & Subsidiaries 106

Recent Developments 108

Strategy And Business Planning 108

Jul 21, 2017: Endo to Restructure Manufacturing Network 108

Financial Announcements 109

Aug 08, 2018: Endo reports second-quarter 2018 financial results 109

May 08, 2018: Endo Reports First-Quarter 2018 Financial Results 111

Feb 27, 2018: Endo Reports Fourth-Quarter And Full-Year 2017 Financial Results 113

Nov 09, 2017: Endo Reports Third-Quarter 2017 Financial Results 115

Oct 30, 2017: Endo Announces Certain Preliminary Financial Results for Third-Quarter 2017 and Affirms Selected 2017 Financial Guidance 117

Aug 08, 2017: Endo Reports Second-Quarter 2017 Financial Results 118

May 09, 2017: Endo Reports First-Quarter 2017 Financial Results 120

Feb 28, 2017: Endo Reports Fourth-Quarter And Full-Year 2016 Financial Results 123

Corporate Communications 126

Aug 02, 2018: Endo announces appointment of Laure Park as senior vice president investor relations and corporate affairs 126

Nov 08, 2017: Endo Announces Appointment of Dr. Sharad S. Mansukani to Board of Directors and Resignation of Mr. Douglas S. Ingram 127

Legal and Regulatory 128

Jun 11, 2018: Endo Announces Master Settlement Agreement Allowing for Resolution of Known Testosterone Replacement Therapy Product Liability Claims and Entry of Significant Case Management Order 128

Apr 02, 2018: Endo Agrees to Extend Temporary Stay of FDA Litigation 129

Jan 24, 2018: Endo Agrees to FDA's Request to Seek Temporary Litigation Stay 130

Jun 07, 2017: Endo Announces Entry of Significant Case Management Order in Mesh Multidistrict Litigation 131

Other Significant Developments 132

Jan 26, 2017: Endo Announces Actions to Drive Greater Efficiency and Business Alignment 132

Appendix 133

Methodology 133

About GlobalData 133

Contact Us 133

Disclaimer 133


List Of Figure

List of Figures

Endo International Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Endo International Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Endo International Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Endo International Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Endo International Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Endo International Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9

Endo International Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Endo International Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

Endo International Plc, Medical Devices Deals, 2012 to YTD 2018 13


List Of Table

List of Tables

Endo International Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Endo International Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Endo International Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9

Endo International Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Endo International Plc, Deals By Therapy Area, 2012 to YTD 2018 11

Endo International Plc, Medical Devices Deals, 2012 to YTD 2018 13

Endo International Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14

Endo International Acquires Portfolio of Branded and Generic Products 18

Endo International Completes Acquisition of Sumavel DosePro Migraine Therapy Business from Zogenix 19

Par Pharma to Acquire Certain Assets of Nuray Chemicals for USD20 Million 20

Paladin Labs To Acquire Antibiotic Binotal In Latin America From Bayer 21

Par Pharma Completes Acquisition Of Generic Products From Watson Pharma And Actavis 22

Endo Pharma Acquires US Patents For Oxymorphone From Johnson Matthey 23

Endo International Sells Grupo Farmaceutico Somar to Advent International 24

Altaris Capital Partners Completes Acquisition Of HealthTronics From Endo Health Solutions For USD 130 Million 25

TPG Capital Completes Acquisition Of Par Pharma, Generic Drug Company, For USD 1.9 Billion 26

Endo Enters into Distribution Agreement with Bioprojet SCR 28

IntelGenx Enters into Co-Development Agreement with Endo Ventures 29

ARIAD Pharma Enters into Distribution Agreement with Paladin 30

Vyrix Pharma Enters Into Distribution Agreement With Paladin Labs For Zertane 31

IntelGenx Enters Into Development And Commercialization Agreement With Par Pharma For Two New Products 32

Auxilium Pharma Enter Into Co-Development Agreement with Swedish Orphan Biovitrum For Xiapex 33

Moberg Extends Distribution Agreement With Paladin Labs For Kerasal Nail 34

GVK Biosciences Enters Into Research Agreement With Endo Pharma 35

Paladin Labs Enters Into Distribution Agreement With Allergy Therapeutics For Pollinex-R 36

Paladin Labs Enters Into Distribution Agreement With Moberg Derma For Emtrix 37

Par Pharma Enters Into Distribution Agreement With AstraZeneca For Atacand HCT 38

Auxilium Pharma Enters Into Co-Promotion Agreement With GlaxoSmithKline For Testim 1% 39

Mersana Therapeutics Enters Into Co-Development Agreement With Endo Pharma 40

Endo Ventures Enters into Licensing Agreement with Nevakar 41

Paladin Labs Enters into Licensing Agreement with Veloxis Pharma 42

Endo International Amends Licensing Agreement with BioSpecifics Technologies 43

Endo Pharma Holdings Amends Licensing Agreement with Grunenthal 44

Auxilium Exercises Option For Licensing Agreement With Biospecifics To Include Potential Treatment of Cellulite As Additional Indication 45

QrxPharma Enters Into Licensing Agreement With Paladin Labs For Moxduo 47

Auxilium Pharma Enters Into Licensing Agreement With Actelion Pharma For XIAFLEX 49

Sucampo Pharma and R-Tech Ueno Enter into Licensing Agreement with Par Pharma 51

Paladin Labs Enters Into Licensing Agreement With Bioniche Life Sciences 52

Paladin Labs Enters Into Licensing Agreement With Apeiron Biologics For APN311 54

Par Pharma Enters Into Licensing Agreement With Handa Pharma For Seroquel XR 55

Paladin Labs Enters Into Licensing Agreement With Dynamiclear For Dynamiclear Rapid 56

Nuvo Research Enters Into Licensing Agreement With Paladin Labs For Synera 57

Par Pharma Enters Into Licensing Agreement With Handa Pharma For ANDA 58

Endo International Raises USD2.3 Billion in Public Offering of Shares 59

Endo International Prices Private Placement of 5.875% Notes Due 2024 for USD300 Million 61

Endo Prices Private Placement of Notes Due 2023 for USD1.6 Billion 62

Endo International Prices Private Placement of 6% Notes Due 2023 for USD1.64 Billion 63

Endo International Prices Private Placement of 6% Notes Due 2025 for USD1.2 Billion 64

Endo International Completes Private Placement of 5.375% Notes Due 2023 for USD750 Million 65

Endo Health Solutions Completes Private Placement Of Notes Due 2022 For USD 700 Million 66

Auxilium Pharma Completes Public Offering Of Notes Due 2018 For USD 350 Million 67

Par Pharma Completes Private Placement Of Notes Due 2020 For USD 490 Million 68

Lannett Acquires Portfolio of Generic Products from Endo International 69

Mayne Pharma Acquires Commercial Rights to Fentanyl TDS from Par Pharma 70

Rising Pharma to Acquire Three ANDAs from Endo International 71

Braeburn Pharma Acquires Risperidone Implant from Endo Pharma 72

Nuvo Research Reacquires Pennsaid Rights from Paladin Labs 73

Rising Pharma Acquires Doxercalciferol, Paricalcitol and Dutasteride from Par Pharma 74

Trendlines Acquires Intellectual Property from Endo 75

AsanaBioSciences Completes Acquisition of Drug Discovery Platform from Endo Pharma 76

Endo Ventures and Par Pharma to Acquire Somerset Therapeutics from Meddham Holdings 77

Par Formulations to Acquire Wintac 78

Acino Pharma Acquires Litha Healthcare from Endo International 79

Endo International Acquires Par Pharma from TPG Capital for USD8.05 Billion 80

Par Pharma Acquires Innoteq for USD27 Million 82

Endo International Acquires Auxilium Pharma for USD2.6 Billion 83

Par Pharma Reportedly Acquires Ethics Bio Lab 85

Endo International Completes Acquisition of Dava Pharma for USD600 Million 86

Endo International Completes Acquisition of Grupo Farmaceutico Somar 87

Endo Health Solutions Completes Acquisition Of Paladin Labs For USD 1.6 Billion 88

Par Pharma Acquires JHP Group for USD488 Million 91

Endo Health Solutions Completes Acquisition Of Boca Pharmacal For USD 225 Million 92

Paladin Labs Acquires Triton Pharma 94

Paladin Labs Completes Acquisition Of Allon Therapeutics 95

Auxilium Pharma Acquires Actient From GTRC 96

Paladin Labs Completes Acquisition Of Majority Stake In Ativa Pharma 98

Paladin Labs Completes Acquisition Of Remaining 55.01% Stake In Pharmaplan, Generic Pharma Company 99

Litha Healthcare Group Completes Acquisition Of Pharmaplan From Paladin Labs For USD 60.7 Million 100

Par Pharma Completes Acquisition Of Edict Pharma, Generic Pharma Company, For USD 24.9 Million 102

Endo International Plc, Key Competitors 103

Endo International Plc, Key Employees 104

Endo International Plc, Other Locations 106

Endo International Plc, Subsidiaries 106

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Endo International Plc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Endo International Plc (Endo) is a specialty healthcare company that develops, manufactures and commercializes various branded pharmaceutical products, generic pharmaceuticals and other products through its operating companies. It sells generic products principally in the US in various categories including urology, pain management, central nervous system (CNS) disorders, immunosuppression, cancer, cardiovascular diseases and women's health, among others. The company offers branded pharmaceuticals for conditions related to urology, orthopedics, endocrinology and pain management. Endo also provides over-the-counter (OTC) products, which include dermatological products and anti-infectives. The company sells its products through independent wholesale distributors, to retailers, government agencies, doctors, clinics, independent retail and specialty pharmacies and independent specialty distributors. Endo is headquartered in Dublin, Ireland.

Endo International Plc (ENDP)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 6

List of Figures 7

Endo International Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Endo International Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9

Endo International Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Endo International Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

Endo International Plc, Medical Devices Deals, 2012 to YTD 2018 13

Endo International Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14

Endo International Plc, Pharmaceuticals & Healthcare, Deal Details 18

Asset Purchase 18

Endo International Acquires Portfolio of Branded and Generic Products 18

Endo International Completes Acquisition of Sumavel DosePro Migraine Therapy Business from Zogenix 19

Par Pharma to Acquire Certain Assets of Nuray Chemicals for USD20 Million 20

Paladin Labs To Acquire Antibiotic Binotal In Latin America From Bayer 21

Par Pharma Completes Acquisition Of Generic Products From Watson Pharma And Actavis 22

Endo Pharma Acquires US Patents For Oxymorphone From Johnson Matthey 23

Private Equity 24

Endo International Sells Grupo Farmaceutico Somar to Advent International 24

Altaris Capital Partners Completes Acquisition Of HealthTronics From Endo Health Solutions For USD 130 Million 25

TPG Capital Completes Acquisition Of Par Pharma, Generic Drug Company, For USD 1.9 Billion 26

Partnerships 28

Endo Enters into Distribution Agreement with Bioprojet SCR 28

IntelGenx Enters into Co-Development Agreement with Endo Ventures 29

ARIAD Pharma Enters into Distribution Agreement with Paladin 30

Vyrix Pharma Enters Into Distribution Agreement With Paladin Labs For Zertane 31

IntelGenx Enters Into Development And Commercialization Agreement With Par Pharma For Two New Products 32

Auxilium Pharma Enter Into Co-Development Agreement with Swedish Orphan Biovitrum For Xiapex 33

Moberg Extends Distribution Agreement With Paladin Labs For Kerasal Nail 34

GVK Biosciences Enters Into Research Agreement With Endo Pharma 35

Paladin Labs Enters Into Distribution Agreement With Allergy Therapeutics For Pollinex-R 36

Paladin Labs Enters Into Distribution Agreement With Moberg Derma For Emtrix 37

Par Pharma Enters Into Distribution Agreement With AstraZeneca For Atacand HCT 38

Auxilium Pharma Enters Into Co-Promotion Agreement With GlaxoSmithKline For Testim 1% 39

Mersana Therapeutics Enters Into Co-Development Agreement With Endo Pharma 40

Licensing Agreements 41

Endo Ventures Enters into Licensing Agreement with Nevakar 41

Paladin Labs Enters into Licensing Agreement with Veloxis Pharma 42

Endo International Amends Licensing Agreement with BioSpecifics Technologies 43

Endo Pharma Holdings Amends Licensing Agreement with Grunenthal 44

Auxilium Exercises Option For Licensing Agreement With Biospecifics To Include Potential Treatment of Cellulite As Additional Indication 45

QrxPharma Enters Into Licensing Agreement With Paladin Labs For Moxduo 47

Auxilium Pharma Enters Into Licensing Agreement With Actelion Pharma For XIAFLEX 49

Sucampo Pharma and R-Tech Ueno Enter into Licensing Agreement with Par Pharma 51

Paladin Labs Enters Into Licensing Agreement With Bioniche Life Sciences 52

Paladin Labs Enters Into Licensing Agreement With Apeiron Biologics For APN311 54

Par Pharma Enters Into Licensing Agreement With Handa Pharma For Seroquel XR 55

Paladin Labs Enters Into Licensing Agreement With Dynamiclear For Dynamiclear Rapid 56

Nuvo Research Enters Into Licensing Agreement With Paladin Labs For Synera 57

Par Pharma Enters Into Licensing Agreement With Handa Pharma For ANDA 58

Equity Offering 59

Endo International Raises USD2.3 Billion in Public Offering of Shares 59

Debt Offering 61

Endo International Prices Private Placement of 5.875% Notes Due 2024 for USD300 Million 61

Endo Prices Private Placement of Notes Due 2023 for USD1.6 Billion 62

Endo International Prices Private Placement of 6% Notes Due 2023 for USD1.64 Billion 63

Endo International Prices Private Placement of 6% Notes Due 2025 for USD1.2 Billion 64

Endo International Completes Private Placement of 5.375% Notes Due 2023 for USD750 Million 65

Endo Health Solutions Completes Private Placement Of Notes Due 2022 For USD 700 Million 66

Auxilium Pharma Completes Public Offering Of Notes Due 2018 For USD 350 Million 67

Par Pharma Completes Private Placement Of Notes Due 2020 For USD 490 Million 68

Asset Transactions 69

Lannett Acquires Portfolio of Generic Products from Endo International 69

Mayne Pharma Acquires Commercial Rights to Fentanyl TDS from Par Pharma 70

Rising Pharma to Acquire Three ANDAs from Endo International 71

Braeburn Pharma Acquires Risperidone Implant from Endo Pharma 72

Nuvo Research Reacquires Pennsaid Rights from Paladin Labs 73

Rising Pharma Acquires Doxercalciferol, Paricalcitol and Dutasteride from Par Pharma 74

Trendlines Acquires Intellectual Property from Endo 75

AsanaBioSciences Completes Acquisition of Drug Discovery Platform from Endo Pharma 76

Acquisition 77

Endo Ventures and Par Pharma to Acquire Somerset Therapeutics from Meddham Holdings 77

Par Formulations to Acquire Wintac 78

Acino Pharma Acquires Litha Healthcare from Endo International 79

Endo International Acquires Par Pharma from TPG Capital for USD8.05 Billion 80

Par Pharma Acquires Innoteq for USD27 Million 82

Endo International Acquires Auxilium Pharma for USD2.6 Billion 83

Par Pharma Reportedly Acquires Ethics Bio Lab 85

Endo International Completes Acquisition of Dava Pharma for USD600 Million 86

Endo International Completes Acquisition of Grupo Farmaceutico Somar 87

Endo Health Solutions Completes Acquisition Of Paladin Labs For USD 1.6 Billion 88

Par Pharma Acquires JHP Group for USD488 Million 91

Endo Health Solutions Completes Acquisition Of Boca Pharmacal For USD 225 Million 92

Paladin Labs Acquires Triton Pharma 94

Paladin Labs Completes Acquisition Of Allon Therapeutics 95

Auxilium Pharma Acquires Actient From GTRC 96

Paladin Labs Completes Acquisition Of Majority Stake In Ativa Pharma 98

Paladin Labs Completes Acquisition Of Remaining 55.01% Stake In Pharmaplan, Generic Pharma Company 99

Litha Healthcare Group Completes Acquisition Of Pharmaplan From Paladin Labs For USD 60.7 Million 100

Par Pharma Completes Acquisition Of Edict Pharma, Generic Pharma Company, For USD 24.9 Million 102

Endo International Plc-Key Competitors 103

Endo International Plc-Key Employees 104

Endo International Plc-Locations And Subsidiaries 106

Head Office 106

Other Locations & Subsidiaries 106

Recent Developments 108

Strategy And Business Planning 108

Jul 21, 2017: Endo to Restructure Manufacturing Network 108

Financial Announcements 109

Aug 08, 2018: Endo reports second-quarter 2018 financial results 109

May 08, 2018: Endo Reports First-Quarter 2018 Financial Results 111

Feb 27, 2018: Endo Reports Fourth-Quarter And Full-Year 2017 Financial Results 113

Nov 09, 2017: Endo Reports Third-Quarter 2017 Financial Results 115

Oct 30, 2017: Endo Announces Certain Preliminary Financial Results for Third-Quarter 2017 and Affirms Selected 2017 Financial Guidance 117

Aug 08, 2017: Endo Reports Second-Quarter 2017 Financial Results 118

May 09, 2017: Endo Reports First-Quarter 2017 Financial Results 120

Feb 28, 2017: Endo Reports Fourth-Quarter And Full-Year 2016 Financial Results 123

Corporate Communications 126

Aug 02, 2018: Endo announces appointment of Laure Park as senior vice president investor relations and corporate affairs 126

Nov 08, 2017: Endo Announces Appointment of Dr. Sharad S. Mansukani to Board of Directors and Resignation of Mr. Douglas S. Ingram 127

Legal and Regulatory 128

Jun 11, 2018: Endo Announces Master Settlement Agreement Allowing for Resolution of Known Testosterone Replacement Therapy Product Liability Claims and Entry of Significant Case Management Order 128

Apr 02, 2018: Endo Agrees to Extend Temporary Stay of FDA Litigation 129

Jan 24, 2018: Endo Agrees to FDA's Request to Seek Temporary Litigation Stay 130

Jun 07, 2017: Endo Announces Entry of Significant Case Management Order in Mesh Multidistrict Litigation 131

Other Significant Developments 132

Jan 26, 2017: Endo Announces Actions to Drive Greater Efficiency and Business Alignment 132

Appendix 133

Methodology 133

About GlobalData 133

Contact Us 133

Disclaimer 133


List Of Figure

List of Figures

Endo International Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Endo International Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Endo International Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Endo International Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Endo International Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Endo International Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9

Endo International Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Endo International Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

Endo International Plc, Medical Devices Deals, 2012 to YTD 2018 13


List Of Table

List of Tables

Endo International Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Endo International Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Endo International Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9

Endo International Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Endo International Plc, Deals By Therapy Area, 2012 to YTD 2018 11

Endo International Plc, Medical Devices Deals, 2012 to YTD 2018 13

Endo International Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14

Endo International Acquires Portfolio of Branded and Generic Products 18

Endo International Completes Acquisition of Sumavel DosePro Migraine Therapy Business from Zogenix 19

Par Pharma to Acquire Certain Assets of Nuray Chemicals for USD20 Million 20

Paladin Labs To Acquire Antibiotic Binotal In Latin America From Bayer 21

Par Pharma Completes Acquisition Of Generic Products From Watson Pharma And Actavis 22

Endo Pharma Acquires US Patents For Oxymorphone From Johnson Matthey 23

Endo International Sells Grupo Farmaceutico Somar to Advent International 24

Altaris Capital Partners Completes Acquisition Of HealthTronics From Endo Health Solutions For USD 130 Million 25

TPG Capital Completes Acquisition Of Par Pharma, Generic Drug Company, For USD 1.9 Billion 26

Endo Enters into Distribution Agreement with Bioprojet SCR 28

IntelGenx Enters into Co-Development Agreement with Endo Ventures 29

ARIAD Pharma Enters into Distribution Agreement with Paladin 30

Vyrix Pharma Enters Into Distribution Agreement With Paladin Labs For Zertane 31

IntelGenx Enters Into Development And Commercialization Agreement With Par Pharma For Two New Products 32

Auxilium Pharma Enter Into Co-Development Agreement with Swedish Orphan Biovitrum For Xiapex 33

Moberg Extends Distribution Agreement With Paladin Labs For Kerasal Nail 34

GVK Biosciences Enters Into Research Agreement With Endo Pharma 35

Paladin Labs Enters Into Distribution Agreement With Allergy Therapeutics For Pollinex-R 36

Paladin Labs Enters Into Distribution Agreement With Moberg Derma For Emtrix 37

Par Pharma Enters Into Distribution Agreement With AstraZeneca For Atacand HCT 38

Auxilium Pharma Enters Into Co-Promotion Agreement With GlaxoSmithKline For Testim 1% 39

Mersana Therapeutics Enters Into Co-Development Agreement With Endo Pharma 40

Endo Ventures Enters into Licensing Agreement with Nevakar 41

Paladin Labs Enters into Licensing Agreement with Veloxis Pharma 42

Endo International Amends Licensing Agreement with BioSpecifics Technologies 43

Endo Pharma Holdings Amends Licensing Agreement with Grunenthal 44

Auxilium Exercises Option For Licensing Agreement With Biospecifics To Include Potential Treatment of Cellulite As Additional Indication 45

QrxPharma Enters Into Licensing Agreement With Paladin Labs For Moxduo 47

Auxilium Pharma Enters Into Licensing Agreement With Actelion Pharma For XIAFLEX 49

Sucampo Pharma and R-Tech Ueno Enter into Licensing Agreement with Par Pharma 51

Paladin Labs Enters Into Licensing Agreement With Bioniche Life Sciences 52

Paladin Labs Enters Into Licensing Agreement With Apeiron Biologics For APN311 54

Par Pharma Enters Into Licensing Agreement With Handa Pharma For Seroquel XR 55

Paladin Labs Enters Into Licensing Agreement With Dynamiclear For Dynamiclear Rapid 56

Nuvo Research Enters Into Licensing Agreement With Paladin Labs For Synera 57

Par Pharma Enters Into Licensing Agreement With Handa Pharma For ANDA 58

Endo International Raises USD2.3 Billion in Public Offering of Shares 59

Endo International Prices Private Placement of 5.875% Notes Due 2024 for USD300 Million 61

Endo Prices Private Placement of Notes Due 2023 for USD1.6 Billion 62

Endo International Prices Private Placement of 6% Notes Due 2023 for USD1.64 Billion 63

Endo International Prices Private Placement of 6% Notes Due 2025 for USD1.2 Billion 64

Endo International Completes Private Placement of 5.375% Notes Due 2023 for USD750 Million 65

Endo Health Solutions Completes Private Placement Of Notes Due 2022 For USD 700 Million 66

Auxilium Pharma Completes Public Offering Of Notes Due 2018 For USD 350 Million 67

Par Pharma Completes Private Placement Of Notes Due 2020 For USD 490 Million 68

Lannett Acquires Portfolio of Generic Products from Endo International 69

Mayne Pharma Acquires Commercial Rights to Fentanyl TDS from Par Pharma 70

Rising Pharma to Acquire Three ANDAs from Endo International 71

Braeburn Pharma Acquires Risperidone Implant from Endo Pharma 72

Nuvo Research Reacquires Pennsaid Rights from Paladin Labs 73

Rising Pharma Acquires Doxercalciferol, Paricalcitol and Dutasteride from Par Pharma 74

Trendlines Acquires Intellectual Property from Endo 75

AsanaBioSciences Completes Acquisition of Drug Discovery Platform from Endo Pharma 76

Endo Ventures and Par Pharma to Acquire Somerset Therapeutics from Meddham Holdings 77

Par Formulations to Acquire Wintac 78

Acino Pharma Acquires Litha Healthcare from Endo International 79

Endo International Acquires Par Pharma from TPG Capital for USD8.05 Billion 80

Par Pharma Acquires Innoteq for USD27 Million 82

Endo International Acquires Auxilium Pharma for USD2.6 Billion 83

Par Pharma Reportedly Acquires Ethics Bio Lab 85

Endo International Completes Acquisition of Dava Pharma for USD600 Million 86

Endo International Completes Acquisition of Grupo Farmaceutico Somar 87

Endo Health Solutions Completes Acquisition Of Paladin Labs For USD 1.6 Billion 88

Par Pharma Acquires JHP Group for USD488 Million 91

Endo Health Solutions Completes Acquisition Of Boca Pharmacal For USD 225 Million 92

Paladin Labs Acquires Triton Pharma 94

Paladin Labs Completes Acquisition Of Allon Therapeutics 95

Auxilium Pharma Acquires Actient From GTRC 96

Paladin Labs Completes Acquisition Of Majority Stake In Ativa Pharma 98

Paladin Labs Completes Acquisition Of Remaining 55.01% Stake In Pharmaplan, Generic Pharma Company 99

Litha Healthcare Group Completes Acquisition Of Pharmaplan From Paladin Labs For USD 60.7 Million 100

Par Pharma Completes Acquisition Of Edict Pharma, Generic Pharma Company, For USD 24.9 Million 102

Endo International Plc, Key Competitors 103

Endo International Plc, Key Employees 104

Endo International Plc, Other Locations 106

Endo International Plc, Subsidiaries 106

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Endo International Plc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.